Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Payment of Outstanding Purchase Consideration
Settlement of purchase consideration due to the promoter company for the acquisition of the API business spin-off.
Capital Expenditure Requirements
Funding capital expenditure for capacity expansion and infrastructure enhancements at manufacturing plants.
General Corporate Purposes
Funding strategic initiatives and general corporate requirements.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Glenmark Life Sciences Limited is a prominent developer and manufacturer of high-value, non-commoditized active pharmaceutical ingredients (APIs) focusing on chronic therapeutic areas. The company specializes in APIs for cardiovascular disease, central nervous system disorders, pain management, and diabetes, alongside offering contract development and manufacturing organization (CDMO) services to global pharmaceutical clients. Originally incorporated as the API manufacturing arm of Glenmark Pharmaceuticals Limited, the business operates four state-of-the-art manufacturing facilities located in Ankleshwar, Dahej, Mohol, and Kurkumbh. These manufacturing plants maintain global regulatory approvals from major authorities, including the United States Food and Drug Administration (US FDA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and the European Directorate for the Quality of Medicines (EDQM). The enterprise exports its active pharmaceutical ingredients to over 65 countries across North America, Europe, Japan, Latin America, and India. By combining advanced process research capabilities with scalable manufacturing infrastructure, the organization continues to expand its CDMO service portfolio and bolster long-term commercial partnerships with leading global generic drug manufacturers.
The company raised ₹454.08 crore by allocating 6,306,660 equity shares at ₹720 per share to 19 anchor investors, including prominent funds such as SBI Mutual Fund, HDFC Mutual Fund, ICICI Prudential Mutual Fund, HSBC, and Nomura.
Source: RHP • Analysis provided for informational purposes
Last Updated: 26 July 2026, 12:25 AM
Strong Position in High-Value Chronic APIs
The company specializes in non-commoditized APIs for chronic therapeutic segments, generating stable demand and high margin profiles across global markets.
Established Global Presence and Regulatory Track Record
Facilities are accredited by leading regulatory authorities including US FDA and PMDA, enabling exports to over 65 countries and deep client relationships with top generic drugmakers.
Integrated R&D and Manufacturing Capabilities
Modern manufacturing plants coupled with dedicated research units support rapid process development, commercial scale-up, and expanding CDMO service offerings.
Dependence on Key Therapeutic Segments
A significant portion of revenues comes from cardiovascular and CNS drug APIs, making performance vulnerable to shifts in generic market demand or regulatory changes in those categories.
Stringent Regulatory Compliance Standards
Operations require strict adherence to international healthcare standards, and any adverse observations during regulatory inspections could impact manufacturing or export approvals.
Concentration of Customer and Geographical Revenues
Revenue relies heavily on key generic pharmaceutical clients and major export markets, exposing the business to pricing pressure or regional regulatory adjustments.
Glenmark Life Sciences Limited
Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413213, Maharashtra, India
View on Maps →No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.